Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gentler chemo combo aims to keep older lung cancer patients on treatment longer

NCT ID NCT06731413

Recruiting now Disease control Sponsor: Virginia Commonwealth University Source: ClinicalTrials.gov ↗

First seen Mar 14, 2026 · Last updated May 15, 2026 · Updated 8 times

Summary

This study is for adults aged 70 or older, or those who are frail, with advanced non-small cell lung cancer that has a low PD-L1 score. The goal is to see if using a reduced dose of chemotherapy together with an immunotherapy drug (anti-PD-1) causes fewer side effects that force people to stop chemotherapy. About 40 participants will receive this combination as their first treatment for advanced disease, and researchers will track how many can stay on chemotherapy and how well the cancer responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Virginia Commonwealth University

    RECRUITING

    Richmond, Virginia, 23298, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADVANCED NON-SMALL CELL LUNG CANCER METASTATIC NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER NSCLC